Palbociclib
Inhibitors
| Trivial name | NULL |
| Catalog Number | CS-T-38566 |
| Alternative Name(s) | 5-(piperazin-1-yl)pyridin-2-yl]amino]-8H-pyrido[2,3-d]pyrimidin-7-one;6-acetyl-8-cyclopentyl-5-methyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)pyrido[2,3-d]pyrimidin-7(8H)-one |
| Research Area | Palbociclib (also known as compound number ) is an experimental drug for the treatment of breast cancer being developed by Pfizer. It is a selective inhibitor of the cyclin-dependent kinases CDK4 and CDK6. |
| Molecular Formula | C24H29N7O2 |
| CAS# | 571190-30-2 |
| Purity | >98% |
| Inchi | NULL |
| Inchi Key | NULL |
| SMILES | O=C1N(C2CCCC2)C3=NC(NC4=CC=C(N5CCNCC5)C=N4)=NC=C3C(C)=C1C(C)=O |
| Beilstein Registry Number | NULL |
| Condensed Formula | NULL |
| EC Number | NULL |
| PubChem Chemical Structure ID | NULL |
| Size | 500 g |
| Supplier Page | https://www.clearsynth.com/en/CST38566.html |
| Additional Information | NULL |